Evaluation and Management of Elevated Alkaline Phosphatase

Initial Assessment

• The American College of Gastroenterology recommends obtaining at least two consecutive ALP measurements (>2 weeks apart) to establish baseline and assess stability, as fluctuations >30% may indicate different etiologies 1, 2
• Determine tissue origin by checking GGT or ALP isoenzymes (liver vs. bone vs. intestinal) to distinguish between hepatobiliary, bone, or other tissue origin 1, 3
• Evaluate for accompanying abnormalities in other liver tests (bilirubin, aminotransferases) which help distinguish between cholestatic and hepatocellular patterns 1
• Review medication list thoroughly as drug-induced cholestasis is a common reversible cause 3

Diagnostic Algorithm

• If GGT is elevated with ALP, proceed with hepatobiliary evaluation 3
• If GGT is normal with elevated ALP, consider bone disease as source 3
• Abdominal ultrasound is the first-line imaging modality to assess for biliary obstruction, liver parenchymal disease, and gallstones 3
• Look specifically for dilated intra- or extrahepatic bile ducts 3

Common Etiologies to Consider

• Primary biliary cholangitis and primary sclerosing cholangitis are hepatobiliary causes of elevated ALP 3
• Drug-induced cholestasis is a common reversible cause of elevated ALP 3
• Infiltrative liver diseases (sarcoidosis, amyloidosis, metastases) can cause elevated ALP 3
• X-linked hypophosphatemia is a bone cause of elevated ALP 4

Management Principles

• Treat the underlying cause, not the laboratory value itself 1
• For cholestatic liver diseases like Primary Biliary Cholangitis, consider ursodeoxycholic acid 1
• For bone disease like Paget's disease, consider bisphosphonates 1
• For X-linked hypophosphatemia, combination of oral phosphorus and active vitamin D (calcitriol or alfacalcidol) 1

Special Considerations

• In patients with autoimmune hepatitis, elevated ALP that doesn't normalize rapidly with treatment should prompt evaluation for overlap syndromes, particularly primary sclerosing cholangitis 3
• In clinical trials for PSC, alkaline phosphatase >10× upper limit normal should be set as the upper limit for exclusion criteria in early phase trials 2
• In oncology patients, ALP should be routinely monitored before the administration of each cycle of treatment or at least monthly 5

When to Refer to Specialist

• ALP remains elevated after 6 months despite normal initial workup 3
• Evidence of biliary obstruction on imaging 3
• Presence of other abnormal liver tests or symptoms suggesting liver disease 3
• ALP >3× upper limit of normal without obvious cause 3